Bronchodilator reversibility in patients with asthma and persistent airflow limitation

Lancet Respir Med. 2022 Nov;10(11):e94-e95. doi: 10.1016/S2213-2600(22)00363-0.

Authors

Ernesto Crisafulli¹, Giulia Sartori², Vincenzo Patruno³, Alberto Fantin³

Affiliations

¹ Department of Medicine, Respiratory Medicine Unit, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, 37124, Italy. Electronic address: ernesto.crisafulli@univr.it.
² Department of Medicine, Respiratory Medicine Unit, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, 37124, Italy.
³ Department of Pulmonology, S. Maria della Misericordia University Hospital, Udine, Italy.

PMID: 36332640
DOI: 10.1016/S2213-2600(22)00363-0

No abstract available

Publication types

Letter
Comment

MeSH terms

Asthma* / drug therapy
Bronchodilator Agents* / therapeutic use
Forced Expiratory Volume
Humans
Lung

Substances

Bronchodilator Agents